Skip to main content

Table 3 Total lymphocytes count (TLC) at start and at end of treatment

From: Total lymphocyte count in cancer patients with lymphopenia treated with intravenous vitamin C: Results of an observational study

  TLC at start of treatment [cells/μL] TLC at end of treatment [cells/μL] Difference (end – start)[cells/μL] probability estimatea
All patients n = 48
 Mean value ± SD;
 range
902 ± 414;
130–1499
1113 ± 466;
220–1135
211 ± 442;
−1110–1900
p = 0.0018
 25% Percentile 532.5 742.5 25.0
 50% Percentile (Median) 920.0 1135.0 115.0
 75% Percentile 1315.0 1440.0 395.0
Patients with severe lymphopenia (lymphocytes < 1000/μL) n = 25
 Mean value ± SD;
 range
551 ± 212;
130–960
919 ± 447;
380–2420
368 ± 449;
−110–1900
p = 0.0004
 25% Percentile 390.0 585.0 30.0
 50% Percentile (Median) 540.0 820.0 240.0
 75% Percentile 705.0 1180.0 610.0
Patients without moderate lymphopenia (lymphocytes 1000–1500/μL) n = 23
 Mean value ± SD
 range
1283 ± 161; 1000–1499 1323 ± 396;
220–1870
40 ± 372;
−1110–660
p = 0.6105
 25% Percentile 1120.0 1150.0 20.0
 50% Percentile (Median) 1320.0 1400.0 100.0
 75% Percentile 1180.0 1620.0 180.0
  1. SD standard deviation
  2. aThe one-sample t-test (two-sided) with α = 5% was applied for statistical testing of the null hypothesis that the mean changes between start and after 4 weeks of treatment are equal to 0
\